B-hPD-1/hLAG3 mice_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

Please input keywords

Order

*Country

한국

미국

일본

중국

영국

호주

프랑스

독일

이탈리아

싱가포르

인도

러시아

캐나다

스위스

기타 국가

*Province

*City

*Name

*Telephone

*Company

*Position

*Email

*Verification code

*Verification Code

Home

동물/세포 모델

동물/세포모델

Humanized Mouse Models

Humanizad Mouse Models

Text

B-hPD-1/hLAG3 mice

Strain Name	C57BL/6-Pdcd1^{tm1(PDCD1)Bcgen} Lag3^{tm1(LAG3)Bcgen}/Bcgen	Common Name	B-hPD-1/hLAG3 mice
Background	C57BL/6	Catalog number	120520
Related Genes	PD-1 (Programmed death-1) ； LAG3 (Lymphocyte activation gene 3, CD223)
NCBI Gene ID	18566,16768

Protein expression analysis

Strain specific PD-1 and LAG3 expression analysis in homozygous B-hPD-1/hLAG3 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hLAG3 (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-PD-1 and anti-LAG3 antibody. Mouse PD-1 and LAG3 were detectable in WT mice while mouse LAG3 was also detectable in homozygous B-hPD-1/hLAG3, due to the anti-mouse LAG3 antibody cross-reacts with human LAG3. Human PD-1 and LAG3 were exclusively detectable in homozygous B-hPD-1/hLAG3 but not WT mice.

Analysis of spleen leukocytes cell subpopulations in B-hPD-1/hLAG3 mice

from clipboard

Analysis of spleen leukocyte subpopulations by FACS

Splenocytes were isolated from female C57BL/6 and B-hPD-1/hLAG3 mice (n=3, 6 week-old) Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for CD45 population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T, B, NK, Monocyte, DC and macrophage cells in homozygous B-hPD-1/hLAG3 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1/hLAG3 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in spleen.

Analysis of spleen T cell subpopulations in B-hPD-1/hLAG3 mice

from clipboard

Analysis of spleen T cell subpopulations by FACS

Splenocytes were isolated from female C57BL/6 and B-hPD-1/hLAG3 mice (n=3, 6 week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, and Treg cells in homozygous B-hPD-1/hLAG3 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1/hLAG3 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell sub types in spleen. Values are expressed as mean ± SEM.

Analysis of blood leukocytes cell subpopulations in B-hPD-1/hLAG3 mice

from clipboard

Analysis of blood leukocyte subpopulations by FACS. Blood were isolated from female C57BL/6 and B-hPD-1/hLAG3 mice (n=3, 6 week-old) Flow cytometry analysis of the blood leukocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for CD45 population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T, B, NK, Monocyte, DC and macrophage cells in homozygous B-hPD-1/hLAG3 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1/hLAG3 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in spleen.

Analysis of blood T cell subpopulations in B-hPD-1/hLAG3 mice

from clipboard

Analysis of blood T cell subpopulations by FACS

Blood were isolated from female C57BL/6 and B-hPD-1/hLAG3 mice (n=3, 6 week-old). Flow cytometry analysis of the blood leukocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, and Treg cells in homozygous B-hPD-1/hLAG3 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1/hLAG3 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell sub types in spleen. Values are expressed as mean ± SEM.

Blood routine test in B-hPD-1/hLAG3 mice

from clipboard

Complete blood count (CBC). Blood from female C57BL/6 and B-hPD-1/hLAG3 mice (n=3, 6 week-old) was collected and analyzed for CBC. There was no differences among any measurement between C57BL/6 and B-hPD-1/hLAG3 mice, indicating that introduction of hPD-1/hLAG3 in place of its mouse counterpart does not change blood cell composition and morphology. Values are expressed as mean ± SEM.

Combination therapy of anti-human PD-1 antibody and anti-human LAG3 antibody

from clipboard

Antitumor activity of anti-human PD-1 antibody combined with anti-human LAG3 antibody in B-hPD-1/hLAG3 mice. (A) Anti-human PD-1 antibody combined with anti-human LAG3 antibody inhibited MC38 tumor growth in B-hPD-1/hLAG3 mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hLAG3 mice (female, 6-7 week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm³, at which time they were treated with pembrolizumab and anti-human LAG3 antibody with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of pembrolizumab and anti-hLAG3 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hLAG3 mice provides a powerful preclinical model for in vivo evaluating combination therapy efficacy of hPD-1 antibodies and hLAG3 antibodies. Values are expressed as mean ± SEM. (All antibodies were made in house)